Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Blood Sampling (2*8mL Tubes) for Lung Cancer

In clinical trials, patients are selected according to strict eligibility criteria (inclusion and who cannot join). These criteria aim to ensure homogeneity within the trial population, but may omit patients with specific characteristics, comorbidities or co-medications.

Official registry: https://clinicaltrials.gov/study/NCT06481813 · Nantes University Hospital · enrollment listed as 730

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Blood Sampling (2*8mL Tubes), PBMC Sampling (1*8mL Tubes), or Paxgene Sampling. The registry lists allocation as randomized. In clinical trials, patients are selected according to strict eligibility criteria (inclusion and who cannot join).

They plan to enroll about 730 people at 4 sites. Taking part typically means a procedure as part of the study plus check-ins.

Official title (unrewritten)

BREATHE Cohort : Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients

Interventions: Blood Sampling (2*8mL Tubes), PBMC Sampling (1*8mL Tubes), Paxgene Sampling, Extended biopsies of tumor lesions

Primary outcome (registry wording): Overall survival

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Patient newly diagnosed with NSCLC or CPC
  • Cared for at Nantes University Hospital
  • Affiliated or beneficiaries of a social security scheme or similar
  • Treated with a systemic therapy including chemotherapy and/or immunotherapy and/or targeted therapy and/or therapy as part of a clinical trial after agreement from the sponsors of the studies concerned (only in the absence of blinding)
  • Having agreed to participate in this study by signing the biocollection consent
  • Affiliated or beneficiaries of a social security or similar scheme
  • Who have agreed to participate in this study by signing the Biocollection consent form

Public study contact (from the registry)

Elvire PONS-TOSTIVINT, MD PhD

02.40.16.59.30

elvire.pons@chu-nantes.fr

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

4 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT06481813 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06481813?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06481813?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary